July 2, 2018 — Today, Socium Therapeutics announced that Joachim Fensterle, PhD has joined the company’s Scientific Advisory Board. After receiving his PhD in immunology / infection biology from the Max Planck Institute for Infection Biology, Dr. Fensterle moved to the Institute for Medical Radiation Science and Cell Research at the University of Würzburg as head of the working group “Bacterial Tumor Therapy.” At Würzburg, Dr. Fensterle successfully lead a project to to modify a Salmonella strain to be used as an orally, administered therapeutic cancer vaccine platform. Dr. Fensterle continued this work at Aeterna Zentaris GmbH, leading pre-clinical development of a lead clinical candidate from the platform targeting prostate cancer.

Dr. Fensterle currently teaches biotechnology and bioengineering at Rhine-Waal University of Applied Sciences in Kleve, Germany.